11 results about "Muscle disorder" patented technology

Provided herein are compounds of Formula (I): (I), or a pharmaceutically acceptable salt or composition thereof, which are useful in the treatment or management of diseases or disorders mediated by AAK1 activity, muscle diseases and disorders, and other conditions.

Provided is a composition for preventing, improving, or treating muscular disorders including sulfonamide-based compounds or salts thereof. According to the present disclosure, the sulfonamide-based compounds or salts thereof may prevent inhibition of differentiation of myoblasts by regulating the expression of PHF20 and YY1. Accordingly, since the composition may prevent or alleviate muscle loss, promote muscle regeneration, and improve muscle exercise function, balance ability, and grip strength recovery ability through increased muscles and changes in ratio of muscle fibers, the composition may be effectively used for therapeutic agents, foods, or feeds for preventing, improving or treating muscle disorders, and improving muscle functions or muscle mass.

We provide formulations of ion channel modulators. [Solution] The present invention partially relates to compositions or dosage forms comprising condensed heteroaryl compounds useful for preventing and / or treating diseases or conditions associated with abnormal function of voltage-gated sodium ion channels, such as abnormal delayed / persistent sodium currents. Methods for treating diseases or conditions associated with abnormal function of sodium ion channels, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, neuromuscular disorders, trigeminal-autonomic headache (TAC), migraines, cranial nerve disorders or polycranial nerve disorders, and cortical spreading depression (CSD), are also provided herein. In another aspect, the present invention provides methods for producing ion channel modulators.

Provided herein, in certain aspects, are pharmaceutical compositions comprising an HSA-IGF2 fusion protein formulated for subcutaneous administration. As provided herein, are methods of treating muscle disorders, including myotonic dystrophies, comprising administration of a pharmaceutical composition comprising an HSA-IGF2 fusion protein formulated for subcutaneous administration.

The present invention relates to a composition for promoting muscle cell differentiation, or preventing or treating muscle diseases, the composition comprising amentoflavone as an active ingredient. It was confirmed that amentoflavone promotes the differentiation of muscle cells by regulating the expression of muscle-specific markers and promoting creatine kinase activity, and therefore the composition can be effectively used as a composition for promoting muscle cell differentiation, producing cultured meat, or preventing, treating or ameliorating muscle diseases.

The present disclosure relates to compounds capable of inhibiting the ClC-1 ion channel for use in treating, ameliorating and / or preventing multiple sclerosis and other neuromuscular diseases.